China: Experimental Use Exemption Of Patent Infringement - A Brief Comparison Of China And The United States

Generally, the purpose of a patent is to award the patentee a limited market monopoly for disclosing his invention to the public. Experimental use of a patented invention, at least under certain circumstances, should not constitute patent infringement if such a use does not encroach upon the protected market. In many countries, including China and United States, experimental use of a patented invention is exempted, though varying in degree, from patent infringement. Here, we provide a brief comparison of the scope of experimental use exemption in the United States and China.


Historical Development

Historically, United States provides a narrow exemption from patent infringement liability for experimental use. The rationale behind the exemption was that "a man who constructed such a machine merely for philosophical experiments or for the purpose of ascertaining the sufficiency of the machine to produce its described effects" should not be punished.1 This historical trend took a turn in 1984, starting from the case of Roche Products Inc. v. Bolar Pharmaceutical Co., Inc.2

In that case, Bolar conducted bioequivalence studies, seeking FDA approval to market generic flurazepam, before Roche's flurazepam patent expired.3 Roche sued Bolar for patent infringement.4 The trial court (U.S. District Court for the Eastern District of New York) ruled in favor of Bolar, holding no liability under the common law experimental use exemption doctrine.5 On appeal, the U.S. Court of Appeals for the Federal Circuit reversed, holding that the "experimental use" exception is narrow, and does not apply to tests having a commercial objective.6

Soon after the Bolar case, the U.S. Congress enacted the Hatch-Waxman Act as part of the Drug Price Competition and Patent Term Restoration Act of 1984, which seeks to strike a balance between two competing interests, encouraging pioneer research and development on one hand, and enabling competitors to market low-cost generic copies of drugs on the other.7 In particular, the Hatch-Waxman Act overrules Federal Circuit's decision in Roche v. Bolar, providing generic drug makers a "safe harbor" from patent infringement for testing "reasonably related" to obtaining FDA approval of an Abbreviated New Drug Application ("ANDA"). 35 U.S.C. § 271(e)(1). Thus, under the Hatch-Waxman Act, bioequivalence studies conducted in connection with ANDA submissions no longer constitute acts of infringement. This is the so-called "Bolar Exemption." In exchange, the mere paper submission of an ANDA for a drug claimed by an unexpired patent is automatically an act of infringement, even though the generic drug maker does not yet have an approved version of the drug entering the market. 35 U.S.C. § 271(e)(2).

In areas other than pharmaceutical testing for regulatory purposes, it appears that the common law experimental use exemption remains narrow: exemption applies only when the use of a patented invention is for pure scientific curiosity.8 In Madey v. Duke University, Madey sued Duke University for patent infringement and Duke University raised the experimental use defense.9 The Federal Circuit rejected Duke University's arguments, holding that the "experimental use" defense is "very narrow" and is limited to actions performed "for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry."10 The court found that researchconducted at universities not only furthers the university's "legitimate business objectives, including educating and enlightening students and faculty participating in these projects;" but "also serve, for example, to increase the status of the institution and lure lucrative grants, students and faculty."11 Such research at a university therefore is not exempted from patent infringement liability.

Experimental Use Exemption in Pharmaceutical Context (the Bolar Exemption)

Since most of the disputes in the United States relating to experimental use exemption occur under the Hatch-Waxman framework, we discuss below the scope of the statutory exemption as construed by the court. The U.S. Supreme Court has construed section 271(e)(1) broadly to encompass any use reasonably related to the development and submission of information under a federal law that regulates the manufacture, use, or sale of drugs or veterinary biological products.12 For example, the "safe harbor" applies not only to drugs, literally covered by the statutory test, but also to medical devices, not expressly spelled out in the statute.13 The Supreme Court further reinforced that "[the experimental use] exemption from infringement extends to all uses of patented inventions that are reasonably related to the development and submission of any information under the FDCA [Federal Food, Drug, and Cosmetic Act]," including preclinical testing and testing data not ultimately included in the drug application.14

Under the guidance of the U.S. Supreme Court, both the Federal Circuit and various federal district courts have taken quite liberal interpretations of section 271 (e)(1). For example, the Federal Circuit held that the statute does not look to the underlying purposes or intended consequences of a use, so long as the use is reasonably related to the FDA approval.15 One federal district court held that if it was reasonable for a party to believe that there was a decent prospect that the "use" in question would contribute to the generation of information that was likely to be relevant in the FDA approval processes, it should not matter whether other reasonable persons might have concluded that FDA approval could be secured even without the information in question.16 Even after receiving FDA approval, if post-approval studies are "materials the FDA demands in the regulatory process," those studies could still fall within the safe harbor provision.17

Nevertheless, courts have set forth limits on the application of section 271(e)(1). For instance, the Federal Circuit held that the safe harbor under section 271(e)(1) only applies to products that are subject to FDA approval.18 If a product does not need approval from a regulatory body, the 271(e)(1) exemption does not apply.19 Furthermore, studies recommended by a marketing department, not conducted for the purpose of regulatory approval, are not entitled to exemption.20 In addition, a federal district court held that section 271(e)(1) offers no protection to a drug maker's use of a patented invention to develop its own patentable product.21 The rationale was that the section 271(e)(1) safe harbor was designed to allow generic competitors to enter the market with a product that competes with a patented invention at precisely the time the patented invention loses its protected status.22 A drug maker, who develops its own new drug product using a patented invention, cannot take advantage of this safe harbor.23


Historical Development

Experimental use exemption was included in China's very first Patent Law in history, which was enacted in 1984. The Patent Law of 1984 in China states that use of a patent solely for the purposes of scientific research and experimentation shall not be deemed as an act of infringement. There have been relatively few judicial cases concerning experimental use exemption in China. Nevertheless, it was generally interpreted narrowly and was limited to scientific research and experimentations carried out specifically on the patented technology as such. The purpose of such exempted use is to give scientists and researchers freedom to characterize the technology, to look into the effect achieved by the technology, or to further improve the technology.24 Under this interpretation, it may be difficult to consider clinical trials conducted by a generic company for regulatory purposes as being exempted from patent infringement. For instance, in Glaxo v. Southwest Synthetic, the court's decision was in favor of the patentee, holding that regulatory clinical trials by the generic company were not exempted from patent infringement.25

In 2003, the Chinese Supreme People's Court delivered a draft judicial interpretation (for public comments) entitled "Provisions Concerning Several Issues in the Trials of Cases of Dispute over Patent Infringement," which proposed that an act of using a patented invention for the purpose of clinical trials to satisfy regulatory requirements shall be considered to fall into the scope of experimental use exemption. That draft, however, never became legally effective.

The case Sankyo Co., Ltd. v. Beijing Wansheng Drug Indus. Co., Ltd brought a new round of attention to this issue in 2006. In that case, Wansheng used a patented process owned by Sankyo for regulatory purpose. The final judgment found no infringement by Wansheng. However, the decision did not rely upon experimental use exemption. The court did not consider Wansheng's act as being for "business purpose." The court reasoned that the use of Sankyo's patent by Wansheng was necessitated by relevant government regulations, which require clinical trials of the drug to satisfy the requirements for obtaining a license for production; the purpose of the trial was to test the safety and efficacy of the drug but "not directly for sale of it."26 A similar opinion was delivered by the court in Elli Lilly v. Gan & Lee Pharm. in 2007.27

A provision, equivalent to the Bolar exemption in the U.S., was introduced for the first time in China's Patent Law when the Law was amended in 2008, which is currently in effect. Article 69 of the Chinese Patent Law recites "[t]he following shall not be deemed to be patent right infringement: . . . (4) [a]ny person uses the relevant patent specially for the purpose of scientific research and experimentation; and (5) [a]ny person produces, uses, or imports patented drugs or patented medical apparatus and instruments, for the purpose of providing information required for administrative examination and approval, or any other person produces or imports patented drugs or patented medical apparatus and instruments especially for that person".28 Notably, the Chinese Bolar exemption provision exists in parallel with the provision on general experimental use exemption.

Current Practice of Experimental Use Exemption

It does not seem that there are any precedential cases in China's judicial practice concerning experimental use exemption. As mentioned above, however, "experimental use" was generally considered as referring to scientific research and experimentations carried out specifically on the patented technology as such, but not those that are conducted by exploiting the patented technology as a means. This understanding is reflected in a directive delivered by Beijing Higher People's Court in 2013, entitled "Guidelines for Judgment of Patent Infringement"29 ("the Guidelines for patent infringement"), although that directive is not generally binding and is aimed only at providing guidance to the trials of patent cases in various courts in Beijing. In addition, the provisions on experimental use exemption are applicable regardless of whether the use is for a business purpose.

Current Practice of Bolar Exemption

There have not been any concluded cases where the court makes a decision based on the Bolar exemption provided in the Chinese Patent Law. Nevertheless, the court decisions in Sankyo Co., Ltd., v. Beijing Wansheng and Elli Lilly v. Gan & Lee Pharm. could shed some lights in the application of the Bolar exemption in China. As in those cases, the Bolar exemption in China could be applicable to drugs and medical devices that are made according to a patented process, as well as drugs and medical devices that are patented per se. In a regulative directive (on trial) enacted by the State Intellectual Property Office ("SIPO"), entitled "Guidelines for Determination of Patent Infringement and Passing Off," the Chinese Bolar exemption is interpreted as applicable not only to patents on drugs and medical devices as such, but also to those on an active ingredient of a drug, on a process for preparing a drug, on a process for preparing an active ingredient of a drug, on parts specifically for use in a medical device, and on a method of using a medical device.30 This directive is binding on local Intellectual Property Offices, which are government administrative agencies handling patent infringement complaints filed with them.

Furthermore, the Chinese Patent Law does not include sale and offering for sale in the listed acts applicable under the Bolar exemption. Usually, drugs and medical devices cannot be put on market when the regulatory approval process is still ongoing. As to acts of offering for sale such as display on a trade fair, it is believed that such acts have nothing to do with obtaining information for regulatory purposes and should be excluded from the Bolar exemption.31 In fact, these acts are indeed excluded from SIPO's directive noted above.

Another question that arises is whether foreign regulatory approval should be included in the Chinese Bolar exemption. The SIPO seems to believe that it is desirable to include both domestic and foreign regulatory approval in the Bolar exemption32 and it has indeed done so in its directive entitled "Guidelines for Determination of Patent Infringement and Passing Off." However, some courts seem to interpret the Bolar exemption as applicable only domestically.33


The experimental use exemption doctrines in the United States and China are conceptually similar, as both provide infringement exemptions in the experimental use context and in the context of pharmaceutical and medical device approval. However, it is to be noted that in China's codified patent law, experimental use exemption and Bolar exemption are separate, parallel provisions. In other words, Bolar exemption is not construed as being specific to experimental use exemption in the Chinese Patent Law. Perhaps the Chinese legislators were not able to categorize use of a patent for regulatory purpose into experimental use since the former could hardly be considered as pure philosophical use. Indeed, an act of applying for regulatory approval would usually be for the purpose of doing business but have little to do with philosophy.

The doctrines are applied differently in the two countries in several important aspects. For example, the Chinese experimental exemption doctrine appears to focus on the inquiry of how a potential infringer uses a patented technology (experimentation on the patented invention per se or employing the patented invention as a means), rather than the purpose of the use (business or philosophical). The United States, however, focuses on the latter.

Also, the Bolar exemption under 35 U.S.C. § 271(e)(1) encompasses an act of offering to sell or selling a patented invention, while the relevant Chinese statute does not include such an act in the exemption list. Another important difference between the legal frames of the United States and China is China's lack of patent term extension for a patent that covers an approved drug and a proper patent linkage system that links patent enforcement activities with the drug approval process. Thus, the Chinese Bolar exemption is often dubbed as a "naked" Bolar exemption, which offers competitive advantages to the generic drug companies but omits a balancing remedy to innovative drug companies.

Nevertheless, the current Chinese Patent Law is viewed by the authority as commensurate with the current state of the domestic pharmaceutical industry where innovation lags behind its U.S. counterpart. That being said, the innovative pharmaceutical industry in China is growing very fast and may demand further amendment of the Chinese patent and drug registration laws to more properly balance the incentives for innovation and access to affordable medicine.

The Authors thank Kumiko Kitaoka (law clerk at Finnegan) for her legal research and helpful discussion. The Authors also thank Ningling Wang (Managing Partner of Finnegan's Shanghai Office) for her critical input.

This article first appeared in AIPLA Biotech Buzz, January 2015


1. Whittemore v. Cutter, 29 F. Cas. 1120, 1121 (C.C.D. Mass. 1813).

2. Roche Prods. v. Bolar Pharm. Co., 733 F.2d 858, 863 (Fed. Cir. 1984)

3. Id. at 860.

4. Id.

. at 861.

6. Id. at 863.

7. Pub.L. No. 98-417, 98 Stat. 1585 (1984) (38 U.S.C. Section 271(e)(1)-(2) (2000)).

8. Madey v. Duke University, 307 F. 3d 1351, 1362 (Fed. Cir. 2002).

9. Id. at 1352.

10. Id. quoting Embrex, Inc. v. Serv. Eng'g Corp., 216 F.3d 1343, 1349 (Fed. Cir. 2000).

11. Madey,307 F.3d at 1362.

12. Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 663, 110 S.Ct. 2683, 2685 (1990)

13. Id.

14. Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193; 125 S.Ct. 2372; 162 L.Ed. 2d 160; 2005 U.S. LEXIS 4840. (2005)

15. AbTox, Inc. v. Exitron Corporation, 122 F.3d 1019, 1020 (Fed. Cir. 1997). modified 131 F. 3d 1009 (Fed. Cir. 1997).

16. Amgen, Inc. v. Hoechst Marion Roussel, Inc., 3 F. Supp. 2d 104, 106 (D. Mass. 1998)

17. Momenta Pharms., Inc. v. Amphastar Pharms., Inc., 686 F.3d 1348, 1359-60 (Fed. Cir. 2012).

18. Proveris Sci. Corp. v. Innovasystems, Inc., 536 F.3d 1256, 1265-66 (Fed. Cir. 2008)

19. Id.

20. Amgen, Inc. v. ITC, 565 F.3d 846, 852 (Fed. Cir. 2009).

21. PSN Ill., LLC v. Abbott Labs. & Abbott Bioresearch Ctr., Inc., 2011 U.S. Dist. LEXIS 108055(N.D. Ill. Sept. 20, 2011)

22. PSN Ill., LLC v. Abbott Labs. & Abbott Bioresearch Ctr., Inc., 2011 U.S. Dist. LEXIS 108055(N.D. Ill. Sept. 20, 2011)

23. Id.

24. Explication to the Newly-Adapted Patent Law (in Chinese only), written by Legal Affairs Department of the SIPO, Intellectual Property Publishing House Co., Ltd., 2001, pages 366-368.

25. Glaxo v. Southwest Synthetic Pharm. Corp., Ltd., 1995 Chong-Jing-Chu-Zi-406 (Chongqing 1st Interm. People's Ct. 1995).

26. Sankyo Co., Ltd.,v. Beijing Wansheng Drug Indus. Co., Ltd., 2006 Er-Zhong-Min-Chu-Zi-04134 (Beijing 2nd Interm. People's Ct. 2006).

27. Elli Lilly v. Gan & Lee Pharm. 2007 Er-Zhong-Min-Chu-Zi-13419-23 (Beijing 2nd Interm. People's Ct. 2007).

28. Art 69, Patent Law of the People's Republic of China (promulgated Dec 27, 2008, effective Oct 1, 2009), PRC President Order No.8 of 11th NPC. See

29. Art 123, Guideline for judgment of patent infringement. See Chinese only)

30. (in Chinese only), see Part I, Chapter Three, Section 7.

31. Yin Xintian. Introduction to the Patent Law of China (in Chinese only), 835 (Intellectual Property Publishing House Co., Ltd., 2011)

32. Supra. at 836.

33. Art. 124 of the Guidelines for patent infringement.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions